Minnesota senator proposes Bitcoin Act after going from skeptic to believer

Hebei Senlang Biotechnology

company

About

Hebei Senlang Biotechnology is focused on the treatment of immune cells new technology development and application of high-tech enterprises.

Details

Last Funding Type
Series B
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2016
Operating Status
Active

Hebei Senlang Biotechnology is focused on the treatment of immune cells new technology development and application of high-tech enterprises.The company has the CAR-T research base (Senrang CAR-T Research Center) in North China, and has formed a high-barrier technology platform such as innovative CAR structural design, virus and cell culture , which can take into account technical research and development, hospital clinical application Provide high-quality and effective cellular immunotherapy support for hematological tumors, solid tumors and other tumor diseases, immune system diseases and other patients.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Hebei Senlang Biotechnology has raised a total of — in funding over 2 rounds. Their latest funding was raised on Dec 1, 2018 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 1, 2018 Series B 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Hebei Senlang Biotechnology is funded by 2 investors. Hebei Xianchuang and Guochuang Investment are the most recent investors.
Investor Name Lead Investor Funding Round
Hebei Xianchuang Series B
Guochuang Investment Series B